semaglutide fda submission Clears For Cardiac Risk Reduction in Diabetic Patients Novo Nordisk files submission to

By better understanding the connection between stress and seizures, we can work towards better management and prevention of seizures in those with epilepsy

DXA data from the STEP-1 and SURMOUNT-1 trials show meaningful lean mass reduction during GLP-1-driven weight loss: approximately 9.7% of total lean tissue with semaglutide in STEP-1, and 10.9% with tirzepatide in SURMOUNT-1

Fibromyalgia Fibromyalgia is a condition where central pain sensitization, rather than peripheral inflammation, drives the symptom picture

C-peptide for Type 2 Diabetes: In contrast, Type 2 diabetes patients typically have normal or increased levels of C-peptide, which reflects insulin resistance rather than a lack of insulin production